Michael Tsai

Dr. Michael Tsai is a researcher at the University of Minnesota's Laboratory Medicine and Pathology department, affiliated with the Division of Molecular Pathology and Genomics. His career focuses on genetic and phenotypic biomarkers for cardiovascular disease (CVD) risk assessment. He has directed central laboratories for major population studies like the Multi-Ethnic Study of Atherosclerosis (MESA), Genetics of Lipid Lowering Drugs and Diet Network (GOLDN), and the BWELL-Mom Study.

Dr. Tsai pioneered research on low-density lipoprotein (LDL) and high-density lipoprotein (HDL) particle heterogeneities, linking serum triglycerides to lipoprotein sizes and their implications for CVD risk. His work emphasizes non-traditional lipoprotein measurements to improve risk prediction, as documented in his role as a faculty investigator at the Advanced Research and Diagnostics Laboratory (ARDL).